Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Going Home Same Day Versus Overnight After Heart Rhythm Procedure

Compares same-day discharge with an overnight stay after pulmonary vein isolation for atrial fibrillation.

Plain-language title generated from the registry record
Registry title: Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation

Key facts

Where
Lübeck, GermanySee the site

Where in Germany

  • Klinik für RhythmologieLübeck, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Luebeck
Trial code
NCT06598280
Record updated
8 April 2025
Original description
Prospective, randomized, controlled, multicentre study to compare the safety and efficacy of a Same Day Discharge (SDD) protocol in combination with a Perclose ProStyle (PPS) /ProGlide (PPG) suture mediated vascular closure device to the current gold standard: an overnight stay (ONS) protocol associated with manual compression ± figure-of-eight suture for the patients receiving interventional pulmonary vein isolation (PVI).Read full original descriptionShow less

Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation - the SHAzAM-AF Study

Prospective, randomized, controlled, multicentre study to compare the safety and efficacy of a Same Day Discharge (SDD) protocol in combination with a Perclose ProStyle (PPS) /ProGlide (PPG) suture mediated vascular closure device to the current gold standard: an overnight stay (ONS) protocol associated with manual compression ± figure-of-eight suture for the patients receiving interventional pulmonary vein isolation (PVI).

Inclusion: Patients age >=18 years; Elective catheter ablation for atrial fibrillation using 6 to 14 Fr inner diameter introducer sheath with a minimum of 1 and maximum of 2 femoral venous access sites, independent of the energy source use.

Exclusion: Active systemic or cutaneous infection, or inflammation in vicinity of the groin; Platelet count < 50,000 cells/mm3; Body mass index (BMI) > 45 kg/m2 or < 18 kg/m2.

ClinicalTrials.gov NCT06598280